+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review

The effect of the levonorgestrel releasing intrauterine system on endometrial hyperplasia: an Australian study and systematic review

Australian and New Zealand Journal of Obstetrics and Gynaecology 49(3): 316-322

The levonorgestrel intrauterine system (LNG-IUS) provides effective contraception and treatment for menorrhagia and is used to prevent endometrial hyperplasia (EH) in women taking unopposed oestrogens. The aim of this study was to assess whether the LNG-IUS was also a safe and effective treatment for EH and to conduct a systematic review of the literature. A retrospective record review was undertaken in a private gynaecology practice in Brisbane, Australia, and included all women with EH treated with hysterectomy, oral progestins or LNG-IUS between January 2004 and April 2007. Histopathological findings from hysterectomy specimens or endometrial biopsies were used to calculate rates of regression of the EH. Twenty-one women elected to have a hysterectomy and seven of those (33%) had no persisting hyperplasia at surgery. Twenty-six women had a LNG-IUS inserted at initial hysteroscopy dilatation and curettage or shortly afterwards; seven of those elected to proceed to hysterectomy when their diagnosis was known. Among ten women who used oral progestin treatment, 90% showed initial regression; two with recurrent EH were subsequently treated successfully with LNG-IUS. All 21 women (100%), including one with atypia, treated with LNG-IUS for more than seven weeks had normal endometrial histology on subsequent assessment. No women developed endometrial cancer. Pooled analysis of the published literature gave a 96% regression rate for non-atypical EH treated with LNG-IUS. These data contribute further evidence that LNG-IUS is a safe and effective method for treating non-atypical EH. Whether LNG-IUS could provide a safe and cost-effective alternative to hysterectomy for atypical EH warrants further examination.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 056312951

Download citation: RISBibTeXText

PMID: 19566568

DOI: 10.1111/j.1479-828X.2009.00981.x

Related references

Oral progestogens vs levonorgestrel-releasing intrauterine system for endometrial hyperplasia: a systematic review and metaanalysis. American Journal of Obstetrics and Gynecology 203(6): 547.E1-10, 2011

Levonorgestrel-releasing intrauterine system vs oral progestins for non-atypical endometrial hyperplasia: a systematic review and metaanalysis of randomized trials. American Journal of Obstetrics and Gynecology 213(4): 469-478, 2015

The effectiveness of a levonorgestrel-releasing intrauterine system (LNG-IUS) in the treatment of endometrial hyperplasia--a long-term follow-up study. European Journal of Obstetrics, Gynecology, and Reproductive Biology 139(2): 169-175, 2008

Management of Endometrial Hyperplasia With a Levonorgestrel-Releasing Intrauterine System: A Korean Gynecologic-Oncology Group Study. International Journal of Gynecological Cancer 26(4): 711-715, 2017

Levonorgestrel-releasing intrauterine system (LNG-IUS) as an effective treatment option for endometrial hyperplasia: a 15-year follow-up study. Fertility and Sterility 95(1): 420-422, 2011

Progression of atypical endometrial hyperplasia to adenocarcinoma despite intrauterine progesterone treatment with the levonorgestrel-releasing intrauterine system. Obstetrics and Gynecology 111(2 Pt 2): 547-549, 2008

Effects of levonorgestrel-releasing intrauterine system on endometrial estrogen and progesterone receptors in patients with endometrial hyperplasia. Nan Fang Yi Ke Da Xue Xue Bao 32(9): 1350-1354, 2013

Levonorgestrel-releasing intrauterine system and endometrial ablation in heavy menstrual bleeding: a systematic review and meta-analysis. Obstetrics and Gynecology 113(5): 1104-1116, 2009

Levonorgestrel-releasing intrauterine system for atypical endometrial hyperplasia. Cochrane Database of Systematic Reviews 2013(6): Cd009458, 2013

Development of endometrioid adenocarcinoma despite Levonorgestrel-releasing intrauterine system: a case report with discussion and review of the RCOG/BSGE Guideline on the Management of Endometrial Hyperplasia. Clinical Obesity 7(1): 54-57, 2016

The combined GnRH-agonist and intrauterine levonorgestrel-releasing system treatment of complicated atypical hyperplasia and endometrial cancer: a pilot study. Gynecological Endocrinology 28(7): 559-561, 2012

Use of levonorgestrel-releasing intrauterine system in the prevention and treatment of endometrial hyperplasia. Obstetrical and Gynecological Survey 67(11): 726-733, 2013

Management of endometrial hyperplasia with a levonorgestrel-releasing intrauterine system: single arm, prospective multicenter study: Korean gynecologic oncology group study (KGOG2006). Japanese Journal of Clinical Oncology 41(6): 817-819, 2011

Levonorgestrel-releasing intrauterine system (Mirena) as a therapy for endometrial hyperplasia and carcinoma. Acta Obstetricia et Gynecologica Scandinavica 82(6): 580-582, 2003

Treatment of nonatypical and atypical endometrial hyperplasia with a levonorgestrel-releasing intrauterine system. American Journal of Obstetrics & Gynecology 188(5): 1297-1298, 2003